| Year |
Citation |
Score |
| 2023 |
Sun XX, Nosrati Z, Ko J, Lee CM, Bennewith KL, Bally MB. Induced Vascular Normalization-Can One Force Tumors to Surrender to a Better Microenvironment? Pharmaceutics. 15. PMID 37631236 DOI: 10.3390/pharmaceutics15082022 |
0.408 |
|
| 2022 |
Leung AWY, Chen KTJ, Ryan GM, Anantha M, Wretham N, Nosrati Z, Heroux D, Wang L, Chow N, Dai Z, Bally MB. DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 345: 75-90. PMID 35259461 DOI: 10.1016/j.jconrel.2022.03.004 |
0.334 |
|
| 2021 |
van der Meel R, Chen S, Zaifman J, Kulkarni JA, Zhang XRS, Tam YK, Bally MB, Schiffelers RM, Ciufolini MA, Cullis PR, Tam YYC. Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. Small (Weinheim An Der Bergstrasse, Germany). e2103025. PMID 34337865 DOI: 10.1002/smll.202103025 |
0.313 |
|
| 2021 |
Kalra J, Baker J, Song J, Kyle A, Minchinton A, Bally M. Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model. International Journal of Molecular Sciences. 22. PMID 34199298 DOI: 10.3390/ijms22126336 |
0.367 |
|
| 2021 |
Chen KTJ, Militao GGC, Anantha M, Witzigmann D, Leung AWY, Bally MB. Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia. Journal of Controlled Release : Official Journal of the Controlled Release Society. 333: 246-257. PMID 33798663 DOI: 10.1016/j.jconrel.2021.03.042 |
0.339 |
|
| 2020 |
Martin B, Seguin J, Annereau M, Fleury T, Lai-Kuen R, Neri G, Lam A, Bally M, Mignet N, Corvis Y. Preparation of parenteral nanocrystal suspensions of etoposide from the excipient free dry state of the drug to enhance in vivo antitumoral properties. Scientific Reports. 10: 18059. PMID 33093456 DOI: 10.1038/s41598-020-74809-z |
0.415 |
|
| 2020 |
Charest G, Tippayamontri T, Shi M, Wehbe M, Anantha M, Bally M, Sanche L. Concomitant Chemoradiation Therapy with Gold Nanoparticles and Platinum Drugs Co-Encapsulated in Liposomes. International Journal of Molecular Sciences. 21. PMID 32659905 DOI: 10.3390/Ijms21144848 |
0.388 |
|
| 2019 |
Chen KTJ, Anantha M, Leung AWY, Kulkarni JA, Militao GGC, Wehbe M, Sutherland B, Cullis PR, Bally MB. Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use. Drug Delivery and Translational Research. PMID 31482519 DOI: 10.1007/S13346-019-00674-7 |
0.306 |
|
| 2019 |
Gilabert-Oriol R, Sutherland BW, Anantha M, Pallaoro A, Bally MB. Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin. Drug Delivery and Translational Research. PMID 31209826 DOI: 10.1007/s13346-019-00651-0 |
0.309 |
|
| 2018 |
Shi M, Anantha M, Wehbe M, Bally MB, Fortin D, Roy LO, Charest G, Richer M, Paquette B, Sanche L. Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats. Journal of Nanobiotechnology. 16: 77. PMID 30290821 DOI: 10.1186/S12951-018-0404-8 |
0.358 |
|
| 2018 |
Gilabert-Oriol R, Ryan GM, Leung AWY, Firmino NS, Bennewith KL, Bally MB. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. International Journal of Molecular Sciences. 19. PMID 30261606 DOI: 10.3390/Ijms19102922 |
0.322 |
|
| 2017 |
Wehbe M, Malhotra AK, Anantha M, Lo C, Dragowska WH, Dos Santos N, Bally MB. Development of a copper-clioquinol formulation suitable for intravenous use. Drug Delivery and Translational Research. PMID 29247315 DOI: 10.1007/s13346-017-0455-7 |
0.323 |
|
| 2017 |
Chernov L, Deyell RJ, Anantha M, Dos Santos N, Gilabert-Oriol R, Bally MB. Optimization of liposomal topotecan for use in treating neuroblastoma. Cancer Medicine. PMID 28544814 DOI: 10.1002/cam4.1083 |
0.396 |
|
| 2017 |
Voráčová K, Hájek J, Mareš J, Urajová P, Kuzma M, Cheel J, Villunger A, Kapuscik A, Bally M, Novák P, Kabeláč M, Krumschnabel G, Lukeš M, Voloshko L, Kopecký J, et al. The cyanobacterial metabolite nocuolin a is a natural oxadiazine that triggers apoptosis in human cancer cells. Plos One. 12: e0172850. PMID 28253280 DOI: 10.1371/Journal.Pone.0172850 |
0.361 |
|
| 2016 |
Kalra J, Baker J, Kyle A, Minchinton A, Bally M. Abstract B54: Location of tumor burden influences tumor and vascular architecture, necrosis, and nanoparticle delivery Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B54 |
0.503 |
|
| 2016 |
Kalra J, Laderoute K, Renouf D, Shaeffer D, Bally M. Abstract B36: Developing circRNA signatures as a biomarker for the early diagnosis of pancreatic carcinoma Cancer Research. 76. DOI: 10.1158/1538-7445.Nonrna15-B36 |
0.303 |
|
| 2016 |
Wehbe M, Anantha M, Backstrom I, Malhotra A, Edwards K, Bally M. Abstract 2206: Development and characterization of an injectable copper clioquinol formulation: repurposing of a topical antifungal for treatment of cancer Cancer Research. 76: 2206-2206. DOI: 10.1158/1538-7445.Am2016-2206 |
0.365 |
|
| 2015 |
Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 26528901 DOI: 10.1016/J.Jconrel.2015.10.053 |
0.718 |
|
| 2015 |
Kalra J, Dragowska WH, Bally MB. Using Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo Model of Cancer. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 63: 691-709. PMID 25940338 DOI: 10.1369/0022155415587978 |
0.328 |
|
| 2015 |
Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. Journal of Controlled Release : Official Journal of the Controlled Release Society. 199: 72-83. PMID 25497312 DOI: 10.1016/J.Jconrel.2014.11.031 |
0.729 |
|
| 2014 |
Waterhouse DN, Sutherland BW, Santos ND, Masin D, Osooly M, Strutt D, Ostlund C, Anantha M, Harasym N, Manisali I, Wehbe M, Bally MB, Webb MS. Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. Investigational New Drugs. 32: 1071-82. PMID 25064374 DOI: 10.1007/s10637-014-0138-x |
0.677 |
|
| 2014 |
Leung AW, Kalra J, Santos ND, Bally MB, Anglesio MS. Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. Nanomedicine (London, England). 9: 501-22. PMID 24746193 DOI: 10.2217/nnm.13.220 |
0.332 |
|
| 2013 |
Donohue E, Thomas A, Maurer N, Manisali I, Zeisser-Labouebe M, Zisman N, Anderson HJ, Ng SS, Webb M, Bally M, Roberge M. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. Journal of Cancer. 4: 585-96. PMID 24069069 DOI: 10.7150/Jca.7030 |
0.38 |
|
| 2013 |
Hare JI, Neijzen RW, Anantha M, Dos Santos N, Harasym N, Webb MS, Allen TM, Bally MB, Waterhouse DN. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. Plos One. 8: e62349. PMID 23626804 DOI: 10.1371/journal.pone.0062349 |
0.669 |
|
| 2013 |
Verreault M, Weppler SA, Stegeman A, Warburton C, Strutt D, Masin D, Bally MB. Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model. Plos One. 8: e59597. PMID 23555046 DOI: 10.1371/journal.pone.0059597 |
0.319 |
|
| 2013 |
Ahn RW, Barrett SL, Raja MR, Jozefik JK, Spaho L, Chen H, Bally MB, Mazar AP, Avram MJ, Winter JN, Gordon LI, Shea LD, O'Halloran TV, Woodruff TK. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. Plos One. 8: e58491. PMID 23526987 DOI: 10.1371/Journal.Pone.0058491 |
0.353 |
|
| 2013 |
Patankar NA, Pritchard J, van Grinsven M, Osooly M, Bally MB. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 865-77. PMID 23303216 DOI: 10.1158/1078-0432.CCR-12-2459 |
0.333 |
|
| 2013 |
Ho EA, Osooly M, Strutt D, Masin D, Yang Y, Yan H, Bally M. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model. Journal of Pharmaceutical Sciences. 102: 227-36. PMID 23132529 DOI: 10.1002/Jps.23351 |
0.481 |
|
| 2013 |
Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Investigational New Drugs. 31: 46-58. PMID 22615060 DOI: 10.1007/s10637-012-9832-8 |
0.743 |
|
| 2012 |
Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB. Irinophore Câ„¢, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model. Journal of Controlled Release : Official Journal of the Controlled Release Society. 158: 34-43. PMID 22001870 DOI: 10.1016/J.Jconrel.2011.09.095 |
0.731 |
|
| 2011 |
Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB. Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. Nanomedicine (London, England). 6: 1645-54. PMID 22077466 DOI: 10.2217/Nnm.11.140 |
0.736 |
|
| 2011 |
Ho VW, Leung K, Hsu A, Luk B, Lai J, Shen SY, Minchinton AI, Waterhouse D, Bally MB, Lin W, Nelson BH, Sly LM, Krystal G. A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Research. 71: 4484-93. PMID 21673053 DOI: 10.1158/0008-5472.Can-10-3973 |
0.667 |
|
| 2011 |
Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. Bmc Cancer. 11: 124. PMID 21477311 DOI: 10.1186/1471-2407-11-124 |
0.744 |
|
| 2011 |
Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Research. 71: 3364-76. PMID 21415165 DOI: 10.1158/0008-5472.Can-10-4261 |
0.714 |
|
| 2011 |
Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strut D, Osooly M, Masin D, Bally MB. Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267. Cancer Biology & Therapy. 11: 826-38. PMID 21358264 DOI: 10.4161/cbt.11.9.15183 |
0.755 |
|
| 2011 |
Patankar N, Anantha M, Ramsay E, Waterhouse D, Bally M. The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™. Pharmaceutical Research. 28: 848-57. PMID 21181548 DOI: 10.1007/S11095-010-0340-2 |
0.679 |
|
| 2011 |
Thomas AM, Kapanen AI, Hare JI, Ramsay E, Edwards K, Karlsson G, Bally MB. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. Journal of Controlled Release : Official Journal of the Controlled Release Society. 150: 212-9. PMID 21094191 DOI: 10.1016/j.jconrel.2010.11.018 |
0.398 |
|
| 2010 |
Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Amankwa L, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. Journal of Controlled Release : Official Journal of the Controlled Release Society. 144: 332-40. PMID 20202473 DOI: 10.1016/J.Jconrel.2010.02.029 |
0.729 |
|
| 2010 |
Ho EA, Ramsay E, Ginj M, Anantha M, Bregman I, Sy J, Woo J, Osooly-Talesh M, Yapp DT, Bally MB. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties. Journal of Pharmaceutical Sciences. 99: 2839-53. PMID 20091826 DOI: 10.1002/jps.22043 |
0.379 |
|
| 2010 |
Banno B, Ickenstein LM, Chiu GN, Bally MB, Thewalt J, Brief E, Wasan EK. The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. Journal of Pharmaceutical Sciences. 99: 2295-308. PMID 19902527 DOI: 10.1002/jps.21988 |
0.346 |
|
| 2010 |
Lou Y, McDonald PC, Oloumi A, Chia S, Kyle A, Keller Uad, Fotovati A, Gray V, Leung S, Huntsman D, Clarke B, Waterhouse D, Bally M, Roskelley C, Overall C, et al. Abstract 455: Hypoxia induced carbonic anhydrase IX is essential for the growth and metastasis of breast tumors Cancer Research. 70: 455-455. DOI: 10.1158/1538-7445.Am10-455 |
0.722 |
|
| 2010 |
Neijzen RW, Wong M, Anantha M, Waterhouse D, Bally M, Ng SSW, Yapp DT. Abstract 3661: Vascular changes and potentiating secondary drug delivery in colorectal cancer with Irinophore C Cancer Research. 70: 3661-3661. DOI: 10.1158/1538-7445.Am10-3661 |
0.737 |
|
| 2009 |
Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Research : Bcr. 11: R25. PMID 19409087 DOI: 10.1186/Bcr2252 |
0.719 |
|
| 2008 |
Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally M, Klasa RJ. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Molecular Cancer Therapeutics. 7: 749-58. PMID 18375822 DOI: 10.1158/1535-7163.Mct-07-0302 |
0.338 |
|
| 2008 |
Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D, Bally MB. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1208-17. PMID 18281556 DOI: 10.1158/1078-0432.Ccr-07-0780 |
0.738 |
|
| 2008 |
Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, ... ... Bally MB, et al. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Molecular Cancer Therapeutics. 7: 59-70. PMID 18202010 DOI: 10.1158/1535-7163.Mct-07-0329 |
0.713 |
|
| 2008 |
Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D, Bally M. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 68: 607-17. PMID 17904831 DOI: 10.1016/J.Ejpb.2007.08.011 |
0.698 |
|
| 2008 |
Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. International Journal of Pharmaceutics. 349: 38-46. PMID 17728083 DOI: 10.1016/j.ijpharm.2007.07.020 |
0.317 |
|
| 2008 |
Winter JN, Waterhouse D, Ahn R, Chen H, Gordon LI, Jovanovic B, Bally M, O’Halloran T. Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies Blood. 112: 4989-4989. DOI: 10.1182/Blood.V112.11.4989.4989 |
0.737 |
|
| 2007 |
Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Research and Treatment. 106: 319-31. PMID 17347776 DOI: 10.1007/s10549-007-9502-2 |
0.379 |
|
| 2007 |
Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Molecular Cancer Therapeutics. 6: 844-55. PMID 17339368 DOI: 10.1158/1535-7163.Mct-06-0159 |
0.652 |
|
| 2007 |
Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochimica Et Biophysica Acta. 1768: 678-87. PMID 17208196 DOI: 10.1016/j.bbamem.2006.11.014 |
0.339 |
|
| 2007 |
Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. Journal of the National Cancer Institute. 99: 53-63. PMID 17202113 DOI: 10.1093/Jnci/Djk005 |
0.318 |
|
| 2007 |
Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 65: 289-99. PMID 17123800 DOI: 10.1016/j.ejpb.2006.10.007 |
0.443 |
|
| 2007 |
Zastre J, Anantha M, Ramsay E, Bally M. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemotherapy and Pharmacology. 60: 91-102. PMID 17009029 DOI: 10.1007/S00280-006-0353-Z |
0.426 |
|
| 2007 |
Webb MS, Boman NL, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, Bally MB. A cationic liposomal vincristine formulation with improved vincristine retention, extended circulation lifetime and increased anti-tumor activity Letters in Drug Design and Discovery. 4: 426-433. DOI: 10.2174/157018007781387782 |
0.343 |
|
| 2006 |
Waterhouse DN, Bally MB. Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy. Nanomedicine (London, England). 1: 359-63. PMID 17716167 DOI: 10.2217/17435889.1.3.359 |
0.708 |
|
| 2006 |
Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharmaceutical Research. 23: 2575-85. PMID 17086505 DOI: 10.1007/PL00022054 |
0.729 |
|
| 2006 |
Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally M. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharmaceutical Research. 23: 2799-808. PMID 17063397 DOI: 10.1007/S11095-006-9111-5 |
0.348 |
|
| 2006 |
Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magnetic Resonance in Medicine. 56: 1011-8. PMID 17029236 DOI: 10.1002/Mrm.21032 |
0.389 |
|
| 2006 |
Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Zhang YZ, Yapp D, Dragowska W, Dunn S, ... ... Bally MB, et al. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Current Cancer Drug Targets. 6: 455-89. PMID 17017873 DOI: 10.2174/156800906778194586 |
0.727 |
|
| 2006 |
Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Molecular Cancer Therapeutics. 5: 1854-63. PMID 16891472 DOI: 10.1158/1535-7163.MCT-06-0118 |
0.395 |
|
| 2005 |
Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Current Drug Delivery. 2: 341-51. PMID 16305437 DOI: 10.2174/156720105774370294 |
0.397 |
|
| 2005 |
Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharmaceutical Research. 22: 915-22. PMID 15948035 DOI: 10.1007/S11095-005-4586-Z |
0.741 |
|
| 2005 |
Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. Journal of Controlled Release : Official Journal of the Controlled Release Society. 105: 89-105. PMID 15878792 DOI: 10.1016/J.Jconrel.2005.03.007 |
0.719 |
|
| 2005 |
Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods in Enzymology. 391: 71-97. PMID 15721375 DOI: 10.1016/S0076-6879(05)91004-5 |
0.744 |
|
| 2005 |
Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods in Enzymology. 391: 40-57. PMID 15721373 DOI: 10.1016/S0076-6879(05)91002-1 |
0.708 |
|
| 2005 |
Kapanen A, Tucker C, Chikh G, Bally M, Klasa R. Cell Based Assays Completed with the Mantle Cell Lymphoma Cell Lines Z138 and NCEB-1 Indicate That Combinations of Bortezomid and Flavopiridol Interact To Achieve Synergistic Activity. Blood. 106: 2410-2410. DOI: 10.1182/Blood.V106.11.2410.2410 |
0.413 |
|
| 2005 |
Ramsay E, Anantha M, Van Tienen I, Osooly-Talesh M, Laskin J, Bally M. P-108 A fixed dose combination comprising liposomal carboplatin andliposomal innotecan for the treatment of a mutine model of NSCLC Lung Cancer. 49: S142-S143. DOI: 10.1016/S0169-5002(05)80602-6 |
0.317 |
|
| 2004 |
Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7662-70. PMID 15569999 DOI: 10.1158/1078-0432.CCR-04-1036 |
0.368 |
|
| 2004 |
Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Molecular Cancer Research : McR. 2: 606-19. PMID 15561777 |
0.701 |
|
| 2004 |
Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6638-49. PMID 15475454 DOI: 10.1158/1078-0432.Ccr-04-0221 |
0.68 |
|
| 2004 |
Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magnetic Resonance in Medicine. 51: 1153-62. PMID 15170835 DOI: 10.1002/Mrm.20074 |
0.383 |
|
| 2004 |
Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2512-24. PMID 15073131 DOI: 10.1158/1078-0432.CCR-03-0244 |
0.332 |
|
| 2004 |
Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally M. Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 1160-9. PMID 14871996 DOI: 10.1158/1078-0432.Ccr-1044-3 |
0.463 |
|
| 2004 |
Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 728-38. PMID 14760096 DOI: 10.1158/1078-0432.CCR-1131-03 |
0.316 |
|
| 2004 |
Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biology & Therapy. 3: 197-204. PMID 14726684 DOI: 10.4161/Cbt.3.2.622 |
0.729 |
|
| 2004 |
Viglianti B, Michelich C, Abraham S, Colvin O, Yarmolenko P, MacFall J, Bally M, Dewhirst M. Chemodosimetry of in-vivo tumor liposome/drug concentration using MRI International Journal of Radiation Oncology*Biology*Physics. 60: S225-S226. DOI: 10.1016/j.ijrobp.2004.06.182 |
0.365 |
|
| 2003 |
Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. Journal of Experimental Therapeutics & Oncology. 3: 261-71. PMID 14696623 DOI: 10.1111/j.1533-869X.2003.01099.x |
0.733 |
|
| 2003 |
Hu Y, Yan H, Masin D, Ng R, Tan S, Harasym N, Bally M, Mayer L. O-288 Anti-metastatic and anti-tumor efficacy of G3139, a Bcl-2 antisense oligonucleotide, as single agent or in combination with vinorelbine, in murine orthotopic and ectopic xenograft models of human non-small cell lung cancer Lung Cancer. 41: S84. DOI: 10.1016/S0169-5002(03)91946-5 |
0.397 |
|
| 2002 |
Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. International Journal of Pharmaceutics. 241: 57-64. PMID 12086721 DOI: 10.1016/S0378-5173(02)00131-X |
0.637 |
|
| 2001 |
Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety. 24: 903-20. PMID 11735647 DOI: 10.2165/00002018-200124120-00004 |
0.714 |
|
| 2001 |
Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharmaceutical Research. 18: 1331-5. PMID 11683249 DOI: 10.1023/A:1013050330608 |
0.679 |
|
| 2000 |
Webb MS, Sarris AH, Cabanillas F, Mayer LD, Bally MB, Burge C, Cullis PR. Clinical and Preclinical Pharmacology of Liposomal Vincristine Journal of Liposome Research. 10: 501-512. DOI: 10.3109/08982100009031114 |
0.4 |
|
| 2000 |
Mayer LD, Krishna R, Webb M, Bally M. Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications Journal of Liposome Research. 10: 99-115. DOI: 10.3109/08982100009029381 |
0.407 |
|
| 1999 |
Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nature Biotechnology. 17: 775-9. PMID 10429242 DOI: 10.1038/11710 |
0.32 |
|
| 1999 |
Mayer LD, Reamer J, Bally MB. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. Journal of Pharmaceutical Sciences. 88: 96-102. PMID 9874708 DOI: 10.1021/js980202h |
0.323 |
|
| 1999 |
Saxon DN, Mayer LD, Bally MB. Liposomal Anticancer Drugs as Agents to be used in Combination with other Anticancer Agents: Studies on a Liposomal Formulation with two Encapsulated Drugs Journal of Liposome Research. 9: 507-522. DOI: 10.3109/08982109909035550 |
0.321 |
|
| 1998 |
Webb MS, Logan P, Kanter PM, St.-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer Cancer Chemotherapy and Pharmacology. 42: 461-470. PMID 9788572 DOI: 10.1007/s002800050846 |
0.41 |
|
| 1997 |
Harasym TO, Cullis PR, Bally MB. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemotherapy and Pharmacology. 40: 309-17. PMID 9225948 DOI: 10.1007/S002800050662 |
0.35 |
|
| 1997 |
Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. British Journal of Cancer. 75: 169-77. PMID 9010021 DOI: 10.1038/bjc.1997.28 |
0.359 |
|
| 1996 |
Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemotherapy and Pharmacology. 37: 351-5. PMID 8548881 DOI: 10.1007/S002800050396 |
0.314 |
|
| 1995 |
Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. British Journal of Cancer. 71: 482-8. PMID 7880728 DOI: 10.1038/bjc.1995.98 |
0.321 |
|
| 1995 |
Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochimica Et Biophysica Acta. 1238: 147-55. PMID 7548129 DOI: 10.1016/0005-2736(95)00121-I |
0.303 |
|
| 1995 |
Boman NL, Bally MB, Cullis PR, Mayer LD, Webb MS. Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy Journal of Liposome Research. 5: 523-541. DOI: 10.3109/08982109509010240 |
0.439 |
|
| 1994 |
Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemotherapy and Pharmacology. 33: 17-24. PMID 8269584 DOI: 10.1007/Bf00686017 |
0.315 |
|
| 1994 |
Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemotherapy and Pharmacology. 34: 137-46. PMID 8194164 DOI: 10.1007/Bf00685931 |
0.414 |
|
| 1994 |
Mayer LD, Cullis PR, Bally MB. The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin Journal of Liposome Research. 4: 529-553. DOI: 10.3109/08982109409037060 |
0.313 |
|
| 1991 |
Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH gradients and membrane transport in liposomal systems. Trends in Biotechnology. 9: 268-72. PMID 1367566 DOI: 10.1016/0167-7799(91)90088-Y |
0.308 |
|
| 1990 |
Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Letters. 53: 183-90. PMID 2208078 DOI: 10.1016/0304-3835(90)90212-G |
0.423 |
|
| 1989 |
Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemotherapy and Pharmacology. 23: 81-6. PMID 2491964 DOI: 10.1007/Bf00273522 |
0.354 |
|
| Show low-probability matches. |